Rubius gets bump in first day of trading after $241.1M IPO

Cellular therapy company Rubius Therapeutics Inc. (NASDAQ:RUBY) climbed $1.25 to $24.25 in its first day of trading July 18 after it raised $241.1 million through the sale of 10.5 million shares at $23 in a bumped-up IPO. The price valued Rubius at $1.8 billion.

According to BioCentury's BCIQ database, the offering is the largest in size, and results in the highest valuation, for a preclinical stage company's IPO...